Astrana Health (ASTH) plunged nearly 21% Tuesday to $21.65 after TD Cowen lowered its price target and the company announced the scheduling of its upcoming financial results.
The sharp decline erased significant value as the stock fell from Monday's closing price of $27.22.
| ASTH Key Metrics | |
| Current Price | $21.57 |
| Daily Change | -20.76% 🔴 |
| Day Range | $20.68 – $25.42 |
| 52-Week Range | $20.12 – $39.97 |
| Market Cap Range | $1.09B – $1.39B |
The sell-off was primarily triggered after TD Cowen adjusted its outlook for the healthcare company on January 26, 2026.
This downward pressure was further compounded by a broader underperformance in the medical care facilities sector on the same day.
Market data shows the stock reached a session low of $20.68, approaching its 52-week low of $20.12.
Understanding how to read a stock quote can help investors track these critical price levels during periods of heavy selling.
Key Takeaways
- ASTH stock plummeted nearly 21% in a single trading session
- TD Cowen reduced its price target from $40.00 to $35.00
- Company announced Q4 and year-end 2025 earnings call for March 2, 2026
- Astrana Health significantly underperformed its industry peers and the SPY
- TD Cowen maintained its “buy” rating despite the price target reduction
What Triggered Astrana Health's (ASTH) Over 20% Drop?
The primary catalyst for the decline was a double-header of news released on January 26, 2026.
This situation highlights the various factors that influence stock prices, from analyst revisions to earnings anticipation.
First, TD Cowen lowered its price objective for ASTH shares by $5.00. This prompted a negative reaction as investors recalibrated their valuation expectations for the company.
Simultaneously, the company issued a formal announcement regarding its 2025 fourth quarter and year-end financial results.
The scheduling of these results for early March often leads to increased volatility as the market anticipates the upcoming data.
The combination of an analyst target cut and the looming earnings report sparked the heavy sell-off.
The stock experienced high volatility throughout the day. It traded within a range of $20.68 to $25.42 on January 27, marking one of its most active sessions in recent months.
What Are Analysts Saying About ASTH?
Analyst sentiment currently presents a mixed picture of caution and long-term optimism. TD Cowen dropped its price target to $35.00, down from a previous target of $40.00.
This adjustment suggests a more conservative view of the company's near-term growth potential or market conditions.
Despite the reduction in the price target, the firm maintained a “buy” rating on the stock.
This indicates that while they see less immediate upside than before, they still believe the company has favorable fundamentals.
There are currently limited other recent analyst ratings available to provide a broader consensus.
Financial data indicates the stock remains a small-cap security. With a market cap estimated between $1.09 billion and $1.39 billion, the stock can be susceptible to significant price swings when analysts adjust their outlooks.
How Does ASTH's Performance Compare to its Peers and the Market?
Astrana Health significantly underperformed both the broader market and its direct competitors.
While ASTH fell over 20.7%, the medical care facilities industry average decline was just around 2.5%.
This suggests the sell-off was driven by company-specific factors rather than a sector-wide trend.
Direct peers also saw much milder declines. Addus HomeCare Corporation (ADUS) fell about 4%, while LifeStance Health Group (LFST) and The Ensign Group (ENSG) both dropped roughly 3.2%.
Other peers like Surgery Partners (SGRY) and Concentra Group (CON) saw declines of about 2.6%.
| Company | Symbol | Daily Change |
|---|---|---|
| Addus HomeCare Corp | ADUS | -4.03% 🔴 |
| LifeStance Health Group | LFST | -3.28% 🔴 |
| The Ensign Group | ENSG | -3.19% 🔴 |
| Surgery Partners, Inc. | SGRY | -2.62% 🔴 |
| Concentra Group | CON | -2.57% 🔴 |
| Industry Avg | – | -2.54% 🔴 |
| Astrana Health | ASTH | -20.76% 🔴 |
When compared to the broader market, the gap is even wider.
While many investors choose to invest in the S&P 500 index for stability, individual stocks like ASTH carry significantly higher specific risk.
Over the past year, ASTH has delivered a return of almost -42% while the SPY gained over 15%.
What Has Been ASTH's Recent Trading Trend?
The stock has been in a clear downward trajectory for several months. Prior to today's plunge, ASTH closed on January 23 at $27.16 with a volume of 318,281 shares.
It had reached as high as $27.60 on January 22, supported by a market capitalization of $1.39 billion.
The three-month trend has been particularly bearish, with the stock losing over 36% of its value.
This is a sharp contrast to its six-month performance, which showed a more moderate decline of about 10%.
The recent acceleration in losses has brought the stock close to its 52-week low of $20.12.
| Time Period | Price Change | Performance |
|---|---|---|
| 2 Weeks (vs SPY) | -25.90% | 🔴 |
| 1 Month | -15.57% | 🔴 |
| 3 Months | -36.31% | 🔴 |
| 6 Months | -10.32% | 🔴 |
| 1 Year | -42.83% | 🔴 |
Volatility has remained a constant factor for investors. The stock has a beta of 0.98, indicating it moves generally in line with market volatility.
Today's action was an extreme outlier to that historical sensitivity.
Is Astrana Health (ASTH) a Buy After the Sell-Off?
Investors are currently weighing two distinct perspectives. The bull case rests on the fact that TD Cowen maintained its “buy” rating despite the target cut.
Investors using professional stock analysis tools might argue that the stock is now oversold.
They may view it as a cheaper entry point for a company with a target still well above the current price.
On the other hand, the bear case is supported by the massive year-long decline and the consistent underperformance against the SPY.
The stock has lost almost 43% of its value over the last 12 months.
This sustained downward momentum and the recent price target cut suggest that internal or external pressures remain unresolved.
| 🟢 Bull Case | 🔴 Bear Case |
|---|---|
| • TD Cowen maintained “Buy” rating | • Analyst price target cut from $40 to $35 |
| • Potential clarity from March 2 earnings | • 1-year return of -42.8% vs SPY +15.7% |
| • Currently in oversold territory | • Technical breakdown near 52-week lows |
Furthermore, the stock is trading near the bottom of its 52-week range. For some investors, this represents a potential floor.
For others, it signals a lack of support that could lead to further new lows.
What Should Investors Watch Next for Astrana Health (ASTH)?
The most critical date for investors is Monday, March 2, 2026. The company announced that it will release its 2025 results before the market opens.
A conference call is scheduled for 5:30 a.m. PT to discuss the findings.
This report will provide essential clarity on the company's financial health and its trajectory for 2026.
Investors will likely look for updates on revenue growth and profit margins to see if the company can justify the analyst “buy” ratings.
Between now and the earnings release, the stock may continue to see high volatility.
Market participants will watch to see if ASTH can maintain support above its $20.12 annual low or if the current sell-off will breach that level.
The Bottom Line
Astrana Health faces a challenging period as it approaches its year-end earnings report following a massive single-day loss.
While analyst support remains in the form of a “buy” rating, the significant price target cut has shaken investor confidence.
The upcoming March 2 financial results will be the ultimate arbiter of whether today's drop was an overreaction or a necessary valuation adjustment.
For now, the stock remains highly volatile as it trades near its 52-week lows.
